Outcomes Using MARS for Patients With ALF

NCT ID: NCT05594953

Last Updated: 2024-03-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-04-23

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Retrospective chart review will be conducted on patients at Methodist Dallas Medical Center, meeting the inclusion criteria from January 1, 2019 to December 15, 2020 to determine the transplant free survival and overall survival and other secondary outcome measures.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Retrospective chart review will be conducted on patients at Methodist Dallas Medical Center, meeting the inclusion criteria from January 1, 2019 to December 15, 2020 to determine the transplant free survival and overall survival and other secondary outcome measures. Patient's charts will be accessed on EPIC by the PI or delegated study personnel. The investigator's anticipate completion of this study by January 31, 2022.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alcoholic Hepatitis Acute Liver Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

• The patient was diagnosed with: Alcoholic hepatitis; AoCLF; OR Acute fulminant liver failure

• The patient underwent at least one round of dialysis using plasma exchange or MARSTM


All patients who underwent MARS at MDMC will be included in the study population.
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Methodist Health System

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Parvez Mantry, MD

Role: PRINCIPAL_INVESTIGATOR

Methodist

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Methodist Dallas Medical Center

Dallas, Texas, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Crystee Cooper, DHEd

Role: CONTACT

214-947-1280

Zaid Haddadin, MS

Role: CONTACT

214-947-1280

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Crystee Cooper, DHEd

Role: primary

214-947-1280

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

075.HEP.2020.D

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Biomarkers in Liver Failure
NCT02833064 ACTIVE_NOT_RECRUITING
The Liver Care Trial
NCT05855031 RECRUITING NA